Sponsor Led Roundtable: Histology and IHC in CNS Drug Discovery: 2D or 3D? [Preclinical Topic]
24 Jun 2024
Novel Targets
![Sponsor Led Roundtable: Histology and IHC in CNS Drug Discovery: 2D or 3D? [Preclinical Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/partners/Translucence-Bio.png/fit-in/1500x9999/filters:no_upscale())
- How does your team use histology and IHC in their drug discovery efforts and are there any bottlenecks or gaps?
- For therapeutics with complex biodistribution patterns (cell/gene/biologic), is sampling the brain with slice IHC sufficient or would complete staining of the intact brain be beneficial and under what circumstances
- What are the challenges with image data viewing, archiving, analysis and transmission?
- How much of your histology and IHC work needs GLP designation?
- What role for 3D IHC could you conceive of over traditional thin section staining?
Industry Expert
